Organon & Co. (FRA:7XP)

Germany · Delayed Price · Currency is EUR

6.07

-0.05 (-0.82%)

Last updated: Dec 5, 2025, 8:05 AM CET

-59.12% (1Y)

Market Cap	1.60B
Revenue (ttm)	5.37B
Net Income (ttm)	427.00M
Shares Out	n/a
EPS (ttm)	1.63
PE Ratio	3.74
Forward PE	1.89
Dividend	0.32 (5.28%)
Ex-Dividend Date	Nov 20, 2025

Volume	n/a
Average Volume	511
Open	6.07
Previous Close	6.12
Day's Range	6.07 - 6.07
52-Week Range	5.39 - 16.21
Beta	n/a
RSI	39.61
Earnings Date	Feb 12, 2026

About Organon & Co.

Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to... [Read more]

Industry Pharmaceutical Preparations

Founded 1923

Employees 10,000

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 7XP

Full Company Profile

Financial Performance

In 2024, Organon & Co.'s revenue was $6.40 billion, an increase of 2.24% compared to the previous year's $6.26 billion. Earnings were $864.00 million, a decrease of -15.54%.

Financial numbers in USD Financial Statements

News

There is no news available yet.